Brad Margus, M.B.A. (2020)

Brad Margus is the co-founder and chief executive officer (CEO) of Exigence Neurosciences, Inc., a company that intends to explore promising target discovery platforms and therapeutic assets for brain diseases. Previously, Margus co-founded and served as the CEO of Perlegen Sciences, Inc., which developed a massively parallel DNA analysis technology that included the design of photolithographic masks for synthesizing oligonucleotide microarrays, proprietary sample preparation techniques, unique fluidics, new laser scanners and laboratory information systems, and high-throughput data analysis pipelines. Margus also co-founded and served as the CEO of Envoy Therapeutics, Inc., which harnessed a unique technology, identified proteins specifically expressed in the disrupted circuitry of brain diseases, and advanced compounds acting on those proteins toward the clinic. Concurrent with his business career, Margus served as founder and volunteer president of the A-T Children’s Project, a nonprofit organization that coordinates research on ataxia-telangiectasia syndrome (also known as Louis–Bar syndrome), a rare, inherited, neurodegenerative, autosomal recessive disorder that affects the nervous, immune and other body systems. Margus holds an M.B.A. from Harvard University.